Exactech to Present to Investors at Baird’s 2008 Small Cap Healthcare Conference

GAINESVILLE, Fla. -- Exactech Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, will present at Baird's 2008 Small Cap Healthcare Investor Conference on September 10 in New York.

Exactech President David Petty and CFO Jody Phillips will review company performance and growth drivers with investors in a formal presentation and breakout meetings. Baird's Small Cap Healthcare Conference focuses on premier small cap public and private health care companies, highlighting companies that are followed by Baird's healthcare analysts in biotechnology, life sciences, medical technology and specialty pharmaceuticals.

About Exactech
Based in Gainesville, Florida, Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States and Australia, in addition to more than 30 markets in Europe, Asia and Latin America. Additional information about Exactech, Inc. can be found at www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at www.exac.com and www.hawkassociates.com.

An Exactech investment profile is online at www.hawkassociates.com/profile/exac.cfm.

Investors may contact Chief Financial Officer Jody Phillips at 352.377.1140 or Julie Marshall or Frank Hawkins, Hawk Associates at 305.451.1888, e-mail: exactech@hawkassociates.com. To receive e-mail alerts about EXAC, sign up at www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

PDF